Marksans Pharma Launches Shareholder KYC Campaign
Marksans Pharma Limited (NSE: MARKSANS | BSE: 524404) has issued a corporate announcement via BSE informing shareholders about an ongoing campaign focused on KYC (Know Your Customer) updations and shareholder engagement. The primary objective of the campaign is to prevent the transfer of unclaimed dividends to the Investor Education and Protection Fund (IEPF), a statutory fund managed by the Ministry of Corporate Affairs.
Under the provisions of the IEPF Authority (Accounting, Audit, Transfer and Refund) Rules, 2016, companies are required to transfer dividends that remain unclaimed or unpaid for a consecutive period of seven years to the IEPF. Once transferred, shareholders can still claim refunds, but the process involves filing an application with the IEPF Authority, which can be time-consuming. Marksans Pharma's campaign aims to proactively reach out to shareholders so that pending dividends can be credited to their accounts before the statutory deadline.
What the Campaign Covers
The announcement indicates that the campaign extends beyond standard KYC compliance. It seeks to ensure that shareholder records are current and accurate, which is critical for seamless communication regarding dividend entitlements, corporate actions, and annual report dispatch. Outdated address records, inactive email IDs, or unverified bank mandate details can result in failed dividend credit attempts, leading to funds becoming unclaimed over time.
- Verification and updation of shareholder contact and bank details
- Claiming of any pending or unclaimed dividends before the IEPF transfer window
- Ensuring KYC compliance as mandated by Sebi and depositories
- Facilitating smoother dividend payouts in future corporate actions
Why Shareholders Should Act
For Marksans Pharma shareholders who have not updated their KYC records in recent years, this campaign presents a timely opportunity. Unclaimed dividends not only represent a loss of rightful income but can also attract regulatory scrutiny on the company's compliance records. By responding to the company's communication, shareholders can safeguard their dividend entitlements without having to navigate the formal IEPF refund process later.
Shareholders holding physical share certificates as well as those with demat accounts are advised to verify their status. Investors whose dividends have already been transferred to IEPF may still be able to file for a refund through the official IEPF portal, but the process is considerably more involved than simply updating KYC records now.
How to Participate
Shareholders should watch for official communications from Marksans Pharma's Registrar and Transfer Agent, which typically handles such campaigns on behalf of the company. Responses may be accepted through registered post, email, or the RTA's online portal, depending on the instructions provided in the company's communication. Keeping PAN, bank account, and contact details updated across all holdings — including multiple folios — is advisable to avoid discrepancies.
The campaign reflects a broader trend among listed companies to improve shareholder outreach and reduce the volume of unclaimed dividends ahead of regulatory compliance deadlines. Investors are encouraged to review their Marksans Pharma holdings and take appropriate action promptly.
Disclaimer: This article is based on publicly available corporate announcements and is intended for informational purposes only. It does not constitute financial or investment advice. Readers are advised to refer to the company's official disclosures on BSE/NSE or consult a SEBI-registered investment advisor before making any investment decisions.